Machine learning approach informs biology of cancer drug response.

Abstract

BACKGROUND:

The mechanism of action for most cancer drugs is not clear. Large-scale pharmacogenomic cancer cell line datasets offer a rich resource to obtain this knowledge. Here, we present an analysis strategy for revealing biological pathways that contribute to drug response using publicly available pharmacogenomic cancer cell line datasets.

METHODS:

We present a custom machine-learning based approach for identifying biological pathways involved in cancer drug response. We test the utility of our approach with a pan-cancer analysis of ML210, an inhibitor of GPX4, and a melanoma-focused analysis of inhibitors of BRAFV600. We apply our approach to reveal determinants of drug resistance to microtubule inhibitors.

RESULTS:

Our method implicated lipid metabolism and Rac1/cytoskeleton signaling in the context of ML210 and BRAF inhibitor response, respectively. These findings are consistent with current knowledge of how these drugs work. For microtubule inhibitors, our approach implicated Notch and Akt signaling as pathways that associated with response.

CONCLUSIONS:

Our results demonstrate the utility of combining informed feature selection and machine learning algorithms in understanding cancer drug response.

• Authors: Eliot Y Zhu, Adam J Dupuy
• Journal: BMC bioinformatics (BMC Bioinformatics) Vol. 23 Issue 1 Pg. 184 (May 17 2022) ISSN: 1471-2105 [Electronic] England
• PMID: 35581546 (Publication Type: Journal Article)
• Copyright: © 2022. The Author(s).

Chemical References

• Antineoplastic Agents
• Proto-Oncogene Proteins B-raf

Topics

• Antineoplastic Agents (pharmacology, therapeutic use)
• Biology
• Cell Line, Tumor
• Humans
• Machine Learning
• Melanoma (metabolism)
• Proto-Oncogene Proteins B-raf